{
    "clinical_study": {
        "@rank": "68949", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A (Reference)", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment B (Test)", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment C (Test)", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the relative bioavailability of palbociclib hard gelatin capsule\n      formulation (API 41  micrometer and dissolution Level 1) and palbociclib hard gelatin\n      capsule formulation (API 16 micrometer and dissolution Level 2) compared to the palbociclib\n      hard gelatin capsule formulation (API 16 micrometer and dissolution Level 1) after single\n      125 mg oral doses under fed conditions in healthy volunteers."
        }, 
        "brief_title": "Relative Bioavailability For Palbociclib Formulations", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects and/or female subjects with no physical possibility of getting\n             pregnant.\n\n          -  Evidence of a personally signed and dated informed consent document indicating that\n             the subject (or a legal representative) has been informed of all pertinent aspects of\n             the study.\n\n          -  Subjects who are willing and able to comply with all scheduled visits, treatment\n             plan, laboratory tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease.\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy).\n\n          -  A positive urine drug screen.\n\n          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14\n             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of\n             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.\n\n          -  Treatment with an investigational drug within 30 days (or as determined by the local\n             requirement, whichever is longer) preceding the first dose of study medication.\n\n          -  Pregnant females; breastfeeding females; females with physical possibility of getting\n             pregnant ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083640", 
            "org_study_id": "A5481040"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A (Reference)", 
                "description": "125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.", 
                "intervention_name": "Palbociclib Formulation Reference", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B (Test)", 
                "description": "125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1", 
                "intervention_name": "Palbociclib Formulation Test", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C (Test)", 
                "description": "125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2", 
                "intervention_name": "Palbociclib Formulation Test", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "healthy volunteer", 
            "bioavailability", 
            "palbociclib", 
            "formulation"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481040&StudyName=Relative%20Bioavailability%20For%20Palbociclib%20Formulations"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Open-Label, 6 Sequence, 3 Period, Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Relative Bioavailability Of 3 Palbociclib Formulations", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083640"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "2 Days"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}